The latest from CDMOs, CMOs, and suppliers featuring Euroapi, Pharmathen, MilliporeSigma, Hovione, Batavia Biosciences, Hermes Pharma and Sohm.  

Chemicals/Chemical API Manufacturing 
* Euroapi Acquires Oligo CDMO BianoGMP
Biologics Manufacturing 
* Batavia Biosciences Opens Viral Vector & Vaccine Mfg Facility
* MilliporeSigma Opens Second Phase of Biologics Testing Center
Formulation Development/Drug Product Manufacturing 
* Hermes Pharma To Invest $27 M To Expand Oral Dosage Capacity
* Pharmathen acquires Peptide CDMO CBL Patras 
* Hovione Acquires ExtremoChem 
* Sohm Opens New Topical Drug Mfg Facility  

---

Chemicals/Chemical API Manufacturing 

Euroapi Acquires Oligo CDMO BianoGMP 
Euroapi has acquired BianoGMP, a Gera, Germany-based CDMO of oligonucleotides.  

Biano will retain its corporate brand and become a Euroapi company. 

Source: Euroapi 

---

Biologics Manufacturing 

Batavia Biosciences Opens Viral Vector & Vaccine Mfg Facility 
Batavia Biosciences, a Leiden, the Netherlands-based CDMO of viral vectors and vaccines, has opened a GMP-ready manufacturing facility in Bilthoven, the Netherlands.  

The facility maintains up to Grade B cleanroom standards to ensure sterile and safe production environments. Equipped with two upstream suites, the facility is designed for parallel manufacturing of viral vectors and vaccines at volumes reaching 200 liters. 

The facility is a stepping stone toward the launch of a more extensive facility in Leiden. Once operational, the Leiden site is expected to eventually supersede the Bilthoven facility with a daily production capacity planned to reach 576,000 vials.  

Source: Batavia Biosciences 

---

MilliporeSigma Opens Second Phase of Biologics Testing Center  
MilliporeSigma, the life science business of Merck KGaA, has opened the second phase of its new EUR-29 million ($32-million) biologics testing center in China, adding 1,500 square meters to the lab, which opened last year (2022).  The Shanghai facility joins the company’s global biosafety testing network with sites in Singapore; Stirling and Glasgow, UK; and Rockville, Maryland. 

The first phase of investment at the site in China provides testing services for viral clearance studies. The second phase adds capabilities for cell-line characterization. The testing center also offers cGMP-compliant lot-release testing for unprocessed and purified bulk harvest to meet requirements for biologics entering preclinical and clinical studies as well as licensed biologics. 

Source: MilliporeSigma 

---

Formulation Development/Drug Product Manufacturing 

Hermes Pharma To Invest $27 M To Expand Oral Dosage Capacity 
Hermes Pharma, a Pullach, Germany-based CDMO of drug products, will invest EUR 25 million ($27 million) to expand its oral dosage manufacturing capabilities. The investment will give the company new equipment, increased production and storage capacity, and greater operational efficiency. 

More specifically, the investment will add large-volume coating equipment, new filling and packaging lines for oral dosage products and instant drinks, expanded GMP manufacturing space and storage capacity, and improved flow of inventory/goods on the shop floor. 

Source: Hermes Pharma 

---

Pharmathen acquires Peptide CDMO CBL Patras 
Pharmathen, a Marousi, Attica, Greece-based CDMO of drug-delivery and formulation development services, has acquired CBL Patras, a Patras, Greece-based CDMO of peptides. 

CBL offers peptide starting materials and intermediates as well as industrial and commercial-scale manufacturing of proprietary and generic GMP peptides.  

Source: Pharmathen 

---

Hovione has Acquires ExtremoChem 
Hovione has acquired ExtremoChem Lda a start-up company focused on the synthesis, development, and commercialization of bio-inspired synthetic sugars for enhanced stabilization, reduced viscosity and delivery performance of proteins and other biopharmaceuticals. ExtremoChem has developed a library of proprietary sugars, synthetic analogues of natural molecules found in extremophiles, referring to organisms capable of withstanding harsh environments. These sugars have shown potential in overcoming challenges associated with the stabilization of biopharmaceuticals during production, purification, formulation, and transportation. 

Source: Hovione 

---

Sohm Opens New Topical Drug Mfg Facility 
Sohm, a Chino Hills, California-based CDMO of drug products, has opened of a new topical drug facility in Carlsbad, California. The facility features space to manufacture topical products and 2,500 square feet allocated to storage of finished products.  

The facility will have an initial daily capacity of 500 gallons with initial manufactured products of topicals but will be expected to add soft-gel suppositories to its capacity by end of the first quarter of 2024 or the beginning of the second quarter, 2024. 

Full cGMP manufacturing capacity is expected to be completed by December 2023. 

Source: Sohm